Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Sellers Strengthened Their Shorts By 7.7% As Of May 16, 2018

May 16, 2018 - By Carolyn Hewitt

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) had an increase of its shorted shares by 7.7%. In May was announced AQXP’s total 265,700 shorted shares by FINRA. The 246,700 previous shares are up with 7.7%. 5 days will cost AQXP with 57,000 average volume to restore its former position. Float short on Aquinox Pharmaceuticals Inc is 2.13%.

The stock increased 3.52% or $0.45 during the last trading session, reaching $13.25.Aquinox Pharmaceuticals, Inc. has 182,963 shares volume, 111.06% up from normal. AQXP is downtrending and has moved 8.81% since May 16, 2017. The stock underperformed the S&P 500 by 20.36%.

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology.The company has $311.27 million market cap. The firm primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5Â’-phosphatase 1 enzyme, a key regulator of a cellular signaling pathway in immune cells.Last it reported negative earnings. The Company’s lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Coverage

A total of 3 analysts rate Aquinox Pharmaceuticals (NASDAQ:AQXP) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AQXP) has 9 ratings reports on May 16, 2018 according to StockzIntelligence. On Monday, May 14 the firm has “Buy” rating by Canaccord Genuity given. In Monday, November 20 report Canaccord Genuity maintained it with “Buy” rating and $22.0 target. The company rating was maintained by Cantor Fitzgerald on Monday, March 12. On Monday, March 12 Canaccord Genuity maintained the shares of AQXP in report with “Buy” rating. On Sunday, February 11 Cantor Fitzgerald maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) rating. Cantor Fitzgerald has “Buy” rating and $28.0 target. The company rating was maintained by Cantor Fitzgerald on Tuesday, May 8. On Monday, December 11 the stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has “Buy” rating given by Canaccord Genuity. On Tuesday, December 19 the stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) earned “Buy” rating by Canaccord Genuity.

For more Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) news brought out briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results” brought out on May 08, 2018, “Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan” on May 10, 2018, “Aquinox to Present at 2018 UBS Global Healthcare Conference” with a publish date: May 16, 2018, “Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference” and the last “Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference” with publication date: April 26, 2018.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: